Ketamine and Esketamine for Bipolar Depression
February 27, 2025 DOI: 10.64239/pi-qt7204
Summary
AI-generated from the abstractKetamine and esketamine are promising treatments for bipolar depression. In a study of patients receiving twice-weekly treatment, 40% responded and 13% achieved full remission. No immediate manic switches occurred during the intensive phase, but 30% experienced hypomania or mania during the maintenance phase, most episodes mild. Involving family members in monitoring mood changes is recommended. Patients with a history of severe mania or rapid cycling may not be ideal candidates.
Study at a glance
| Characteristics | Review |
|---|---|
| Population | Patients with bipolar depression |
| Interventions | Ketamine Esketamine |
| Key finding | Ketamine and esketamine show promise for bipolar depression with a 40% response rate and 13% full remission, but 30% of patients experienced hypomania or mania during maintenance treatment. |
Abstract
Ketamine and esketamine show promise in bipolar depression, with 40% of patients responding to twice-weekly treatment. Full remission occurs in 13%. No immediate manic switches occurred during intensive treatment, but 30% experienced hypomania/mania during maintenance phase. Most episodes were mild. Consider involving family members in monitoring mood changes. Patients with severe mania or rapid cycling history may not be ideal candidates.